La Jolla Pharmaceutical Company
LJPC
LJPC was delisted on the 19th of August, 2022.
44 hedge funds and large institutions have $77.8M invested in La Jolla Pharmaceutical Company in 2021 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 14 increasing their positions, 17 reducing their positions, and 15 closing their positions.
211% more call options, than puts
Call options by funds: $165K | Put options by funds: $53K
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
10% more capital invested
Capital invested by funds: $70.9M → $77.8M (+$6.89M)
18% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 17
19% less funds holding
Funds holding: 54 → 44 (-10)
67% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
+$2.33M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$280K |
| 3 |
GC
Globeflex Capital
San Diego,
California
|
+$274K |
| 4 |
Bank of New York Mellon
New York
|
+$216K |
| 5 |
HCM
Hollencrest Capital Management
Newport Beach,
California
|
+$167K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$3.55M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$1.84M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$632K |
| 4 |
Two Sigma Advisers
New York
|
-$275K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$252K |
LJPC Hedge Fund Activity: Q4 2021 in Review
44 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in La Jolla Pharmaceutical Company (LJPC) for Q4 2021, worth a combined $77.8M — up 9.7% from $70.9M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of LJPC and 5 opened new positions — a net loss of 10 holders — while 17 trimmed existing stakes and 14 added.
The largest buyer was HealthInvest Partners, adding an estimated $2.33M. The largest seller was Boxer Capital, exiting entirely with an estimated $3.55M sold.
- 44 institutional investors held La Jolla Pharmaceutical Company (LJPC) as of Q4 2021, down from 54 in Q3 2021.
- Funds reported $77.8M of La Jolla Pharmaceutical Company stock for Q4 2021, up 9.7% quarter-over-quarter.
- 5 funds opened new La Jolla Pharmaceutical Company positions in Q4 2021 and 15 closed out, a net change of -10 holders.
- The largest La Jolla Pharmaceutical Company buyer in Q4 2021 was HealthInvest Partners, an estimated $2.33M added.
- The largest La Jolla Pharmaceutical Company seller in Q4 2021 was Boxer Capital, an estimated $3.55M sold.
Based on aggregated 13F filings for Q4 2021.